S Saha1, P B Savage, M Bal. 1. Department of Physiology, University College of Science and Technology, University of Calcutta, Kolkata, West Bengal, India.
Abstract
AIMS: To improve the efficacy of erythromycin, a hydrophobic antibiotic, against multiple antibiotic-resistant gram-negative bacterial pathogens by enhancing their outer membrane permeability. METHODS AND RESULTS: Fifty-one nonrepeat gram-negative bacterial pathogens of various genera, resistant to multiple antibiotics, including erythromycin, were selected by disc agar diffusion tests. The amphiphilic cationic steroid antibiotic, Ceragenin CSA-13, a potent permeabilizer of bacterial outer membranes, reduced the minimum inhibitory concentration of erythromycin in 92% of the bacterial pathogens selected for the test, when supplemented with erythromycin. A synergistic effect of Ceragenin CSA-13 and erythromycin in combination was also observed. Spectrofluorimetric study confirmed that Ceragenin CSA-13 acts by depolarizing the bacterial outer membrane. The toxicity of Ceragenin CSA-13 was evaluated to be insignificant by measuring 'median lethal dose' (LD(50)) on mouse model. CONCLUSIONS: Ceragenin CSA-13 may be useful as an agent to make erythromycin effective against infections caused by multiple antibiotic resistant gram-negative bacteria. SIGNIFICANCE AND IMPACT OF THE STUDY: The outcome of the study suggests erythromycin-Ceragenin combination as a new approach to overcome the problem associated with the rapid emergence of multi-drug-resistant pathogens. The insignificant toxicity of Ceragenin CSA-13, as found, supports the possibility of the application of this compound for human therapeutics.
AIMS: To improve the efficacy of erythromycin, a hydrophobic antibiotic, against multiple antibiotic-resistant gram-negative bacterial pathogens by enhancing their outer membrane permeability. METHODS AND RESULTS: Fifty-one nonrepeat gram-negative bacterial pathogens of various genera, resistant to multiple antibiotics, including erythromycin, were selected by disc agar diffusion tests. The amphiphilic cationic steroid antibiotic, Ceragenin CSA-13, a potent permeabilizer of bacterial outer membranes, reduced the minimum inhibitory concentration of erythromycin in 92% of the bacterial pathogens selected for the test, when supplemented with erythromycin. A synergistic effect of Ceragenin CSA-13 and erythromycin in combination was also observed. Spectrofluorimetric study confirmed that Ceragenin CSA-13 acts by depolarizing the bacterial outer membrane. The toxicity of Ceragenin CSA-13 was evaluated to be insignificant by measuring 'median lethal dose' (LD(50)) on mouse model. CONCLUSIONS:Ceragenin CSA-13 may be useful as an agent to make erythromycin effective against infections caused by multiple antibiotic resistant gram-negative bacteria. SIGNIFICANCE AND IMPACT OF THE STUDY: The outcome of the study suggests erythromycin-Ceragenin combination as a new approach to overcome the problem associated with the rapid emergence of multi-drug-resistant pathogens. The insignificant toxicity of Ceragenin CSA-13, as found, supports the possibility of the application of this compound for human therapeutics.
Authors: Urszula Wnorowska; Katarzyna Niemirowicz; Melissa Myint; Scott L Diamond; Marta Wróblewska; Paul B Savage; Paul A Janmey; Robert Bucki Journal: Antimicrob Agents Chemother Date: 2015-04-13 Impact factor: 5.191
Authors: Elizabeth A Trainor; Katherine E Horton; Paul B Savage; Traci L Testerman; David J McGee Journal: Infect Immun Date: 2010-10-25 Impact factor: 3.441
Authors: K Leszczyńska; A Namiot; K Cruz; F J Byfield; E Won; G Mendez; W Sokołowski; P B Savage; R Bucki; P A Janmey Journal: J Appl Microbiol Date: 2010-10-21 Impact factor: 3.772
Authors: Robert Bucki; Katarzyna Niemirowicz; Urszula Wnorowska; Fitzroy J Byfield; Ewelina Piktel; Marzena Wątek; Paul A Janmey; Paul B Savage Journal: Antimicrob Agents Chemother Date: 2015-07-27 Impact factor: 5.191
Authors: Katarzyna Leszczynska; Dorota Namiot; Fitzroy J Byfield; Katrina Cruz; Malgorzata Zendzian-Piotrowska; David E Fein; Paul B Savage; Scott Diamond; Christopher A McCulloch; Paul A Janmey; Robert Bucki Journal: J Antimicrob Chemother Date: 2012-11-07 Impact factor: 5.790